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An understanding of the mechanisms determining
MYC’s transcriptional and proliferation-promoting
activities in vivo could facilitate approaches for
MYC targeting. However, post-translational mecha-
nisms that control MYC function in vivo are poorly
understood. Here, we demonstrate that MYC phos-
phorylation at serine 62 enhancesMYCaccumulation
on Lamin A/C-associated nuclear structures and that
the protein phosphatase 2A (PP2A) inhibitor protein
CIP2A is required for this process. CIP2A is also crit-
ical for serum-induced MYC phosphorylation and for
MYC-elicited proliferation induction in vitro. Comple-
mentary transgenic approaches and an intestinal
regeneration model further demonstrated the in vivo
importance of CIP2A and serine 62 phosphorylation
forMYCactivity uponDNAdamage. However, target-
ing of CIP2A did not influence the normal function of
intestinal crypt cells. These data underline the impor-
tance of nuclear organization in the regulation ofMYC
phosphorylation, leading to an in vivo demonstration
of a strategy for inhibiting MYC activity without detri-
mental physiological effects.
INTRODUCTION
An understanding of the mechanisms controlling MYC function
in vivo is critical for the development of MYC-targeted therapies.
By using loss-of-function genetic models, MYC has been shown
to be required for proliferation induction in several types of
normal cells, including fibroblasts, intestinal progenitors, and
lymphoid B and T cells (de Alboran et al., 2001; Mateyak et al.,Cell1997; Sansom et al., 2007; Trumpp et al., 2001). Moreover, it
has been demonstrated recently that MYC expression is essen-
tial for intestinal crypt regeneration in response to either irradia-
tion-induced or chemically induced DNA damage (Ashton et al.,
2010; Athineos and Sansom, 2010). Although these studies have
convincingly demonstrated the critical role for aMYC dose for an
in vivo proliferation response, they are not particularly informa-
tive regarding the endogenous mechanisms that regulate
MYC’s activity by post-translation modifications in vivo.
The induction of c-myc mRNA expression after proliferative
stimuli is very rapid and transient, whereas the expression of
the MYC protein is more sustained because of increased protein
stability (Hann, 2006; Lutterbach and Hann, 1994; Sears et al.,
1999; Thomas and Tansey, 2011). Cell culture and in vitro studies
have revealed that the MYC protein is heavily regulated by
various post-translational modifications (Hann, 2006; Lu¨scher
and Vervoorts, 2012). Moreover, several different domains of
MYC are implicated to be critical for its activity in regulating
the expression of its numerous target genes as well as for prolif-
eration regulation (Hann, 2006; Lu¨scher and Vervoorts, 2012;
Meyer and Penn, 2008). Remarkably, despite this knowledge, it
has not been established which of the numerous MYC post-
translational modifications define(s) MYC’s activity in vivo.
A cancerous inhibitor of PP2A, CIP2A, is a recently identified
human oncoprotein (Junttila et al., 2007; Khanna et al., 2013).
Consistent with its role as an inhibitor of ubiquitous serine/thre-
onine phosphatase PP2A that regulates the activity of numerous
cellular signaling pathways (Janssens and Goris, 2001), CIP2A
has been shown to regulate the phosphorylation and activity of
Akt, DapK, E2F1, MYC, and mTORC (Khanna et al., 2013;
Puustinen et al., 2014). However, except for its role in promoting
spermatogenesis (Ventela¨ et al., 2012), the physiological role of
CIP2A is unclear. Also, in vivo, the only so far validated CIP2A
target protein is E2F1 in a murine model of breast cancer (Laine
et al., 2013).Reports 12, 1019–1031, August 11, 2015 ª2015 The Authors 1019
Very recent studies have demonstrated a critical function for
nuclear lamina-associated structures in gene regulation and
chromosomal organization (Arib and Akhtar, 2011; Bukata
et al., 2013; Dechat et al., 2010; Kind et al., 2013; Zullo et al.,
2012). In this work, we demonstrate that serine 62 phosphoryla-
tion promotes MYC recruitment to nuclear Lamin A/C-associ-
ated structures (LASs), where its interaction with CIP2A is
required for retaining this localization and MYC activity. More-
over, by using MYC loss-of-function and phosphorylation mu-
tants and the attenuation of CIP2A, we provide a comprehensive
in vivo approach to validate the importance of MYC serine
62 phosphorylation for the organismal proliferation response.
Together, these results demonstrate an endogenousmechanism
that defines the activation of MYC phosphorylation in vivo.
Because CIP2A is dispensable for normal tissue function and
mousewell-being, these results also indicate potential therapeu-
tic opportunities for the inhibition of MYC activity in vivo without
detrimental effects on normal physiology.
RESULTS
Characterization of the Spatial Nuclear Organization of
the CIP2A-MYC Interaction
To provide a spatial understanding of the CIP2A-mediated regu-
lation of MYC, we first analyzed the subcellular distribution of
CIP2A in HeLa cells in which CIP2A constitutively promotes
the expression of serine 62-phosphorylated MYC and MYC ac-
tivity (Junttila et al., 2007; Niemela¨ et al., 2012). Consistent with
immunofluorescence staining analyses (Figure 1A), the great
majority of CIP2A was expressed in the cytoplasmic fraction of
cells (Figure 1B), but a small fraction was expressed in the nu-
cleus and especially in the insoluble nuclear fraction together
with Lamin A/C (Figure 1B). Importantly, a proximity ligation
assay (PLA) with CIP2A and Lamin A/C primary antibodies re-
vealed a clear CIP2A-Lamin A/C association (Figure 1C). Inter-
estingly, the CIP2A interaction with Lamin A/C is not restricted
to nuclear lamina but is also observed in discrete intranuclear
dots. This is fully consistent with an immunofluorescence (IF)
analysis of the intranuclear localization of Lamin A/C (Figure 1C)
and recently published data showing that many Lamin A/C-con-
taining structures are mobile in the nuclei (Capelson et al., 2010;
Kind et al., 2013).
Next we used a PLA to analyze whether MYC interacts with
Lamin A/C. MYC-Lamin A/C association was observed with a
pattern that resembled CIP2A-Lamin A/C association. The ma-
jority of signals were detected in the nuclear periphery, but
very clear intranuclear interactions were also observed (Fig-
ure 1D; Figure S1A). Importantly, the CIP2A-MYC association,
as shown by PLA, also co-localized with Lamin A/C at the nu-
clear lamina, although, again, intranuclear interactions were
also observed (Figure 1E, b and insets). Serine 62 phosphoryla-
tion of MYC is important for MYC-mediated gene regulation and
protein stability (Hann, 2006; Lu¨scher and Vervoorts, 2012).
Notably, PLA with pS62MYC antibody and CIP2A revealed a
similar pattern of interaction at the nuclear lamina as with an anti-
body that detects the total MYC pool (Figures 1E, c and d, and
1F), indicating that the form of MYC that interacts with CIP2A
is phosphorylated on serine 62. To see whether the pattern of1020 Cell Reports 12, 1019–1031, August 11, 2015 ª2015 The AuthoCIP2A-pS62MYC PLA signals, both at the nuclear lamina and
in the nuclear interior, corresponds to the distribution of
pS62MYC protein, the cells were examined by pS62MYC immu-
nofluorescence staining. As shown in Figure 1G, the distribution
of pS62MYC did resemble the nuclear lamina-enriched punc-
tuate pattern seen with CIP2A-pS62MYC PLA, although, based
on fewer CIP2A-pS62MYC PLA signals (Figure 1E) compared
with signals observed with immunofluorescence staining (Fig-
ure 1G), it is apparent that only a certain fraction of pS62MYC
interacts with CIP2A at any given moment. Importantly, the dis-
tribution pattern of total MYC did not show a similar punctuate
pattern as that observed with pS62MYC IF or by CIP2A-MYC
PLA, and there was no particular enrichment of total MYC IF sig-
nals at the nuclear periphery (Figure 1G). This further indicates
that the form of MYC with which CIP2A interacts at the LAS is
pS62MYC.
These results reveal a selective spatial distribution of
pS62MYC in complex with CIP2A at the LAS.
The Major Fraction of pS62MYC Is Bound to
Proteinaceous Nuclear Structures via a DNA-
Independent Mechanism
Next we addressed, with a classical salt fractionation protocol,
the biochemical basis of the CIP2A and pS62MYC association
with the LAS. As expected, we found that increasing the NaCl
concentration released both pS62MYC and MYC from the insol-
uble to the soluble nuclear fraction (Figure 1H; Figure S1B).
However, compared with MYC, a significant fraction of CIP2A
remained insoluble even in the presence of 500 mM NaCl, and,
as expected, H3 was entirely resistant to this treatment (Fig-
ure 1H; Figure S1B). To further study the potential role of DNA
binding in the nuclear segregation of CIP2A and pS62MYC to
the LAS, the insoluble nuclear fractions isolated without deter-
gent treatment were subjected to DNAase (benzonase) treat-
ment, and the expression of pS62MYC, total MYC, MAX, and
CIP2A was compared between the insoluble pellet and the ben-
zonase eluate. To verify the efficacy of elution of DNA-bound
proteins by benzonase, we show that approximately 70% of
the total H3 was eluted by this treatment (Figures 1I and 1J). Sur-
prisingly, only approximately 20% of pS62MYC, total MYC, or
MAX was eluted by benzonase treatment (Figures 1I and 1J),
whereas, in comparison with H3 and MYC, negligible amounts
of CIP2A were detected in benzonase-treated eluates (Figures
1I and 1J).
These results indicate that CIP2A and the majority of
pS62MYC are bound to the proteinaceous component of the
LAS. Moreover, the association of pS62MYC with the LAS
seems to be mediated by an ionic interaction.
Serine 62Phosphorylation ofMYCDrives Its Association
with the LAS, and CIP2A Is Required to Retain This
Localization
Based on the results above, we rationalized that serine 62 phos-
phorylation of MYC may promote the recruitment of MYC to the
LAS and that, rather than chromatin binding, its interaction with
CIP2Amay be required to retain pS62MYC in these sites of chro-
matin re-organization and transcription regulation (Arib and Akh-
tar, 2011; Kind et al., 2013; Zullo et al., 2012). To study this, wers
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Figure 1. CIP2A and Serine 62-Phosphorylated MYC Interact at Lamin A/C-Associated Proteinaceous Nuclear Structures
(A) Immunofluorescent staining of CIP2A in HeLa cells.
(B) Analysis of subcellular distribution of CIP2A in cytoplasmic (C) soluble nuclear (S) and insoluble nuclear (I) fractions of HeLa cells by high-salt (400 mM NaCl)
nuclear extraction. Lamin A/C and b-tubulin represent nuclear and cytoplasmic markers, respectively.
(C) PLA analysis of the CIP2A-Lamin A/C association in HeLa cells. The specificity of PLA is shown by the lack of PLA signals in a secondary antibody-only control
panel. a: immunofluorescence analysis of Lamin A/C distribution both in the nuclear lamina as well as in the nucleoplasm. ab, antibody.
(D) PLA analysis of the MYC-Lamin A/C association in HeLa cells. White dots are pseudocolor MYC-Lamin A/C PLA signals.
(E) PLA analysis of the CIP2A-MYC and CIP2A-pS62MYC association in HeLa cells. a–d: co-localization of CIP2A-MYC and CIP2A-pS62MYC PLA signals with
Lamin A/C (white dots). The insets in b show detailed images of the association of the CIP2A-MYC PLA signal with Lamin A/C.
(F) Quantitation of CIP2A-MYC and CIP2A-pS62MYC PLA signals at the nuclear lamina and nucleoplasm from (E, b and d).
(G) Immunofluorescence analysis of pS62MYC and total MYC nuclear distribution. The insets highlight the difference in staining pattern between pS62MYC
and MYC.
(H) Quantification of the relative expression of the indicated proteins in the insoluble fraction of HeLa cells subjected to salt extraction fractionation with increasing
NaCl concentrations.
(I) Analysis of the DNA dependence of the CIP2A, pS62MYC, and MYC association with the insoluble nuclear fraction. Histone H3 was used as a control for the
efficacy of elution of DNA-bound proteins.
(J) Quantitation of the protein amount in benzonase eluate relative to the total amount from (I). The samples were loaded on the same gel. Error bars represent
SEM (n = 3).examined the distribution of exogenously expressed wild-type
MYC and two mutants, S62A and T58AMYC, between the insol-
uble and soluble nuclear fractions. We have shown previously
that the functionally inactive MYC S62A mutant (Benassi et al.,
2006; Sears et al., 2000) does not interact with CIP2A in human
cells (Junttila et al., 2007), whereas theMYC T58Amutant, which
is a functional mimic of serine 62-phosphorylated MYC (Benassi
et al., 2006; Hann, 2006; Wang et al., 2011; Yeh et al., 2004), re-
tains full CIP2A-interacting capacity (Junttila et al., 2007).
Notably, the S62A mutant of MYC showed a clearly reduced
accumulation to the insoluble nuclear fraction compared
with wild-type MYC, whereas the CIP2A binding-competent
T58AMYC accumulated very efficiently in the insoluble fractionCell(Figures 2A and 2B). These results are in agreement with PLA re-
sults demonstrating that the form of MYC that is associated with
the LAS is pS62MYC (Figures 1E–1G). To further confirm that the
distribution to the insoluble fraction reflects the differential
association of MYC phosphorylation mutants with the LAS, we
performed a PLA with V5 and Lamin A/C antibodies in cells ex-
pressing equivalent amounts of V5-S62AMYC or V5-T58AMYC
(Figure S2). Consistent with other results, T58AMYC showed a
clearly increased association with Lamin A/C compared with
S62AMYC (Figure 2C).
The results above, together with a PLA and IF analysis of
pS62MYC (Figures 1E and 1G), clearly demonstrate that serine
62 phosphorylation increases MYC’s association with the LAS.Reports 12, 1019–1031, August 11, 2015 ª2015 The Authors 1021
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Figure 2. Serine 62 Phosphorylation of MYC Enhances Its Recruitment to Lamin A/C-Associated Nuclear Structures, and CIP2A Is Required
to Retain This Localization
(A) Western blot analysis of the subnuclear distribution of exogenous V5-tagged WT, S62A, and T58A MYC and pS62MYC in HeLa cells. The fractionation was
done with 150 mM NaCl. V5 antibody was used to detect WT MYC and the S62A and T58A MYC mutants. Exp, experiment.
(B) Quantitation of the ratio of V5-MYC between the insoluble and soluble nuclear fractions from (A). Shown is the mean ± SEM of two experiments.
(C) PLA analysis of the V5-Lamin A/C association in HeLa cells transfected with equivalent amounts of V5-MYCT58A or V5-MYCS62A mutant. Shown is a
quantification of the average number of V5-Lamin A/C PLA signals per cell from 50 cells.
(D) Analysis of subnuclear portioning of pS62MYC and total MYC in CIP2A siRNA-transfected HeLa cells. The indicated salt extraction conditions were used to
either retain MYC in (150 mM) or dissociate MYC from (400 mM) the insoluble fraction. Scr, scrambled.
(E) CIP2A depletion selectively affects pS62MYC localized to the insoluble fraction. Lanes 5 and 7 represent proteins that were extracted from the insoluble
fraction, and the values for the effect of CIP2A depletion on pS62MYC and MYC expression in the insoluble fraction represent a comparison of lanes 2 and 5 for
(legend continued on next page)
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However, whether CIP2A is relevant for the accumulation of
MYC to the LAS has not yet been addressed. To this end, we
studied the subnuclear distribution of pS62MYC and total MYC
in CIP2A small interfering RNA (siRNA)-transfected cells. For
the first part of this experiment, the nuclear proteins were ex-
tracted with low-salt buffer (150 mM NaCl) to preserve MYC’s
association with Lamin A/C. In support of our hypothesis, deple-
tion of CIP2A inhibited the expression of pS62MYC in the Lamin
A/C-enriched insoluble fraction, whereas the expression of total
MYC was inhibited to a much smaller extent (Figures 2D,
compare lanes 2 and 4, and 2E, insoluble). Importantly, the sol-
uble fraction of pS62MYC was insensitive to CIP2A inhibition
(Figures 2D, lanes 1 and 3, and 2E, soluble). To confirm that
the CIP2A-sensitive pS62MYCpool corresponds to the salt-sen-
sitive pool of MYC described in Figure 1H, insoluble proteins
were extracted from CIP2A siRNA-transfected cells in the pres-
ence of 400 mM salt. Also, in this case, the CIP2A-sensitive pool
of MYC was the pS62MYC eluted from the insoluble fraction
(Figures 2D, lanes 5 and 7, and 2E).
CIP2A has been shown to prevent the degradation of MYC,
and this effect is seen more profoundly with pS62MYC than
with total MYC antibody (Junttila et al., 2007). Therefore, we
examined whether CIP2A influences pS62MYC stability in the
insoluble nuclear fraction. Indeed, a cycloheximide (CHX) chase
experiment using both pS62MYC and MYC antibodies revealed
a clear decrease in protein stability upon CIP2ARNAi in the insol-
uble nuclear fraction (Figure 2F). To confirm these results, we
studied the impact of CIP2A depletion in the insoluble nuclear
fraction on a T58A mutant that is resistant to PP2A-mediated
destabilization (Yeh et al., 2004). Indeed, although CIP2A siRNA
effects were observed by using the pS62MYC antibody, which
detects both endogenous MYC and T58A, CIP2A depletion did
not alter the accumulation of MYCT58A in the insoluble nuclear
fraction (Figure 2G).
Together, the results so far demonstrate a function of serine 62
phosphorylation of MYC in promoting its association with the
LAS. These results also demonstrate that CIP2A is not a univer-
sal regulator of MYC but that it selectively supports the stability
of the LAS-associated pool of pS62MYC. As will be explained
later, this newly characterized selectivity of CIP2A toward
spatially segregated pS62MYC may explain the lack of detri-
mental physiological effects of systemic CIP2A inhibition (Laine
et al., 2013; Ventela¨ et al., 2012) compared with the direct inhibi-
tion of MYC (Dubois et al., 2008; Soucek et al., 2008).
CIP2A Is Critical for Serum-Induced pS62MYC
Expression and MYC-Mediated Proliferation Induction
Next we studied the relevance of CIP2A for mitogen-induced
MYC regulation in mouse embryonic fibroblasts (MEFs) isolated
from CIP2A-deficient (CIP2AHOZ) mice (Laine et al., 2013; Ven-
tela¨ et al., 2012) and their wild-type counterparts. Importantly,scrambled siRNA and lanes 4 and 7 for CIP2A siRNA. The expression of MYC and
is the mean + SEM of two experiments.
(F) Effect of CIP2A siRNA on endogenous pS62MYC stability in the insoluble nuc
levels at the indicated time points compared with non-CHX-treated cells. Shown
(G) Western blot analysis of the expression of V5-tagged MYCT58A in the ins
Endogenous pS62MYC is shown as a control for the functional perturbation of C
Cellthe loss of CIP2A clearly inhibited the serum-induced expression
of serine 62-phosphorylated MYC (Figures 3A and 3B). Because
immunoblotting of the samemembrane with an antibody against
total MYC showed an equal impairment in MYC accumulation
(Figures 3A and 3B), we postulate that pS62MYC is the form of
MYC that is most sensitive to mitogenic stimuli. This conclusion
is supported by the preferential induction of pS62MYC protein
expression, compared with total MYC, in wild-typeMEFs treated
with increasing concentrations of serum (Figures 3C and 3D).
Importantly, c-myc mRNA induction was not impaired in
serum-induced CIP2AHOZ MEFs (Figure 3E), further indicating
that the effects on MYC are due to a CIP2A-dependent post-
translational mechanism. Moreover, CIP2AHOZ MEFs showed a
statistically significant decrease in bromodeoxyuridine (BrdU)
incorporation (Figure 3F) and in the re-initiation of the cell cycle
in response to serum induction (Figure 3G), consistent with re-
sults reported previously (Kim et al., 2013). Notably, the effects
of CIP2A loss on MEF cell cycle regulation and proliferation are
not as robust as those reported for MYC-null MEFs (de Alboran
et al., 2001; Meyer and Penn, 2008; Perna et al., 2012), which is
consistent with our conclusion that CIP2A loss affects only a
sub-population of MYC. To provide additional and more direct
evidence that CIP2A supports MYC’s ability to drive cell cycle
activity, we employed conditional MYC-estrogen receptor
(ER)-expressing MCF-10A cells. In these cells, the addition of
4-hydroxytamoxifen activates MYC-ER, and this activation is
sufficient to induce cell cycle re-entry in growth factor-deprived
cultures (Nieminen et al., 2007). Notably, the inhibition of CIP2A
expression resulted in loss of the ability of tamoxifen-activated
MYC-ER to promote the cell cycle (Figure 3H). Importantly,
CIP2A depletion did not affect MYC-ER fusion protein expres-
sion, confirming that CIP2A promotes MYC activity in prolifera-
tion induction (Figure 3I). Unlike in cancer cells (Laine et al.,
2013), CIP2A inhibition in either MCF-10A or MEF cells did not
affect E2F1 expression (Figure S3), providing further support
for a selective role of CIP2A in regulating MYC activity in these
cells.
Together, these results identify CIP2A as a critical endoge-
nous regulator of MYC serine 62 phosphorylation and function
during proliferation induction.
MYC Interacts with CIP2A in Mouse Intestinal Tissue
Intestinal regeneration after DNA damage induced by irradiation
or by cisplatin treatment is fully dependent on MYC dose, and,
therefore, it can be used as a model to address the MYC depen-
dence of the in vivo proliferation response (Ashton et al., 2010;
Athineos and Sansom, 2010; Finch et al., 2009; Muncan et al.,
2006; Sansom et al., 2007). Similar to MYC, we observed
CIP2A immunopositivity in cells of the intestinal crypt, with
reduced expression in the differentiated cells of the villi (Fig-
ure 4A). The specificity of this staining pattern was demonstratedpS62MYC in the soluble fraction was quantified between lanes 1 and 3. Shown
lear fraction. The symbols denote the average pS62MYC and MYC expression
is the mean ± SEM from three independent experiments.
oluble fraction in either scrambled or CIP2A siRNA-transfected HeLa cells.
IP2A function, and Lamin A/C was used as a loading control.
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Figure 3. CIP2A Is a Critical Endogenous Regulator of MYC Phosphorylation and Function during Proliferation Induction
(A) Western blot analysis of pS62MYC, MYC, and CIP2A expression in serum-starved (0h) and serum-stimulated (1h) WT and CIP2AHOZ MEFs. Shown is a
representative result of four independent experiments with similar results.
(B) Quantitation of MYC and pS62MYC protein levels in response to serum induction and normalized to b-actin. Shown is the mean ± SEM of four experiments.
n.s., not significant, Student’s t test.
(C and D) Analysis of induction of pS62MYC protein expression compared with total MYC in wild-type MEFs treated with increasing concentrations of serum.
Shown is the mean ± SEM of three experiments.
(E) RT-PCR analysis of MYC mRNA expression in serum-starved (0h) and serum-stimulated (1h) WT and CIP2AHOZ MEFs. Shown is the mean ± SD of two
independent experiments (Student’s t test).
(F) BrdU incorporation of WT and CIP2AHOZ MEFs 48 hr after seeding either 3,000 or 5,000 cells/well. Shown is the mean ± SD of three independent experiments
(Student’s t test).
(G) Cell cycle analysis of serum-starved (0h) and-serum stimulated (24h) WT and CIP2AHOZ MEFs. Shown is the percentage of cells in either G1/S or G2 phase.
Shown are mean values from three independent experiments (Student’s t test).
(H) Induction of proliferation in MCF-10A-MYC-ER cells transfected with CIP2A or control siRNA (Scr) in hydroxytamoxifen (OHT)-treated cells (MYC active) and/
or control cells (OHT). Shown is the mean ± SD of induction of Ki-67-positive cells from three independent experiments (Student’s t test).
(I) Western blot analysis of MYC-ER fusion protein (molecular weight, 110 kDa) expression in MCF-10A-MYC-ER cells transfected with CIP2A or control siRNA.by a lack of specific staining in CIP2AHOZ tissue (Figure 5A).
Moreover, in situ PLA activity as an indication of an association
between CIP2A and MYC proteins was detected in the nuclei
of intestinal crypt cells (Figures 4B, a, 4C, and 4D). In contrast,
a PLA using only secondary antibodies did not produce any
detectable PLA activity (Figures 4B, b, and 4C). As an additional
control, we show that, in comparison to wild-type tissue, a
clearly smaller number of PLA-positive spots were observed in
intestinal sections of CIP2AHOZ mice (Figures 4E and 4F).
CIP2A Is Dispensable for Normal Intestinal Crypt
Homeostasis but Promotes Intestinal Regeneration in
Response to DNA Damage
MYC is essential for normal crypt structure in the adult intestine
(Muncan et al., 2006; Soucek et al., 2008). On the other hand,
recent analyses have demonstrated normal growth, weight,
development, and lifespan of CIP2AHOZ mice despite a lack of
CIP2A expression in all studied organs (Laine et al., 2013; Ven-
tela¨ et al., 2012). This suggests that the protein interaction be-
tween CIP2A and MYC in intestinal cells may not be essential
for intestinal crypt homeostasis. In line with this hypothesis, a
comparison of BrdU positivity and the number of paneth and
goblet cells in the intestines of wild-type (WT) and CIP2AHOZ
mice did not reveal any indications of disturbance in proliferation
or differentiation of intestinal crypts (Figure S4). Also, CIP2AHOZ1024 Cell Reports 12, 1019–1031, August 11, 2015 ª2015 The Authomice did not reveal any gross changes in crypt architecture
compared with WT mice (Figure S4). These results demonstrate
that CIP2A is dispensable for normal crypt function.
Notably, similar to MYC induction in response to DNA damage
(Ashton et al., 2010; Athineos and Sansom, 2010), the regenerat-
ing intestinal tissue displayed amarked CIP2A upregulation both
at the protein and mRNA levels, whereas the CIP2AHOZ intestine
remained CIP2A-deficient even under these conditions (Figures
5A and 5B). To determine whether increased CIP2A expression
functionally contributes to MYC-dependent intestinal regenera-
tion, crypt regeneration following irradiation was studied in
CIP2AHOZ mice and their wild-type controls. Control intestines
demonstrated a robust regenerative response, and this
response was significantly attenuated in the absence of CIP2A
(Figures 5C and 5D). Additionally, the regenerating crypts
observed in CIP2AHOZ mice were significantly less proliferative
than those of control mice (Figures 5E and 5F), whereas CIP2A
loss did not acutely increase apoptosis induction in intestinal
crypts after irradiation (Figure 5G). To verify that the CIP2A
dependence of intestinal regeneration is a general phenomenon
related to DNA damage, mice were treated systemically with
the chemotherapy agent cisplatin. Importantly, in response to
cisplatin treatment, CIP2AHOZ intestines showed an even more
dramatic perturbation in the regenerative and proliferative
response than in response to irradiation (Figures 5H–5J).rs
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Figure 4. CIP2A Interacts with MYC in Intestinal Tissue
(A) Immunohistochemical staining of endogenous MYC (top) and CIP2A (bottom) expression in intestinal tissue. Scale bars, 50 mm.
(B) CIP2A and MYC physically associate in intestinal cells. Left: Red dots indicate the association of CIP2A and MYC proteins in intestinal tissue, as analyzed by
PLA. Scale bar, 25 mm. a: red arrowheads indicate positive PLA signals in intestinal cell nuclei. b: no PLA signals were detected by using secondary antibodies
(2nd ab) only.
(C) Quantitation of the number of PLA signals in 50 intestinal cells analyzed in (B).
(D) Quantitation of PLA signals that were associated with nuclear DAPI staining in (B).
(E) PLA analysis of the CIP2A-MYC association in WT and CIP2AHOZ mouse intestinal tissues. Scale bar, 25 mm.
(F) Quantitation of number of PLA signals in 50 intestinal cells analyzed in (E).To study whether CIP2A is expressed in Lgr5+ intestinal crypt
stem cell-like cells, we exploited a transgenic mouse model ex-
pressing GFP under the Lgr5 promoter (Metcalfe et al., 2014). As
shown in Figure 5K, CIP2AmRNAwas relatively more expressed
in the GFP-positive (Lgr5+) cell population than in Lgr5 cells.
However, compared with OLFM4, which is a bona fide intestinal
crypt stem cell factor (van der Flier et al., 2009), CIP2A was not
enriched to the same extent (Figure 6K), which is also in accor-
dance with positive CIP2A IHC staining in other intestinal crypt
cells (Figure 4A).
These results demonstrate that CIP2A promotes MYC-depen-
dent intestinal regeneration induced by DNA damage.
CIP2A Is Critical for the Transcriptional Activation of
MYC Targets during Intestinal Regeneration
Next we asked whether the phenotypic outcome in intestinal tis-
sue regeneration in CIP2AHOZmice is truly linked to themodifica-
tion of MYC function. First, we investigated MYC expression
levels in untreated intestines from control and CIP2AHOZ mice
and found no obvious difference (Figure 6A). In addition, upon
regeneration, quantification of the intensity of MYC staining per
cell within the crypt boundaries (Figure 6B, dashed line and in-Cellsets) in 50 consecutive crypts/mouse revealed that MYC immu-
nopositivity in CIP2AHOZ mice within the crypt was at the same
level as in WT crypts (Figure 6C). In addition, and similar to
MEFs, c-mycmRNAwas expressed at equal levels in regenerat-
ing WT and CIP2AHOZ crypts (Figure 6D). However, fully consis-
tent with our in vitro results showing that CIP2A selectively
regulates pS62MYC (Figures 2D and 2E), the irradiation-induced
expression of pS62MYC was inhibited in CIP2AHOZ crypts
(Figures 6E and 6F), and this correlated with the induction of pro-
liferation assessed by Ki67 co-staining (Figures 6E and 6F).
Next we next performed a qRT-PCR analysis of irradiated
wild-type and CIP2AHOZ intestines on a number of MYC target
genes involved in intestinal regeneration (Athineos and Sansom,
2010; Sansom et al., 2007). Of the genes analyzed, all were
significantly downregulated in regenerating guts from CIP2AHOZ
mice compared with controls (Figure 6G). We also confirmed
impaired MYC recruitment to the tiam1 promoter upon CIP2A in-
hibition by siRNA in cultured cells (Figure S5). The MYC and
CIP2A dependence of protein expression for selected MYC
target genes was further confirmed using immunohistochemistry
(IHC) (Figure 6H). Quantification of CDK4 and TIAM1 expression
from sections adjacent sections to those from which MYCReports 12, 1019–1031, August 11, 2015 ª2015 The Authors 1025
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Figure 5. CIP2A Promotes Intestinal Regeneration in Response to DNA Damage
(A) Immunohistochemical staining of CIP2A in control and regenerating small intestines. Tissue from CIP2A-deficient (CIP2AHOZ) mice was used to control for
antibody specificity (bottom). Scale bars, 50 mm.
(B) qRT-PCR analysis for CIP2A in WT, CIP2AHOZ, WT regenerating (Regen) and CIP2AHOZ regenerating small intestine (Student’s t test, n = 3). Error bars
represent the mean ± SD.
(C) H&E staining of regenerating crypts from WT and CIP2AHOZ intestines following irradiation. Scale bars, 50 mm.
(D) Scoring of a number of regenerating crypts in WT and CIP2AHOZ intestines following irradiation (Mann-Whitney test, n = 7 versus 6).
(E) Ki67 staining of regenerating crypts from WT and CIP2AHOZ intestines following irradiation. Scale bars, 50 mm.
(F) Scoring of number of Ki67-positive cells per crypt in WT and CIP2AHOZ intestines following irradiation (Mann-Whitney test, n = 4 versus 5).
(G) CIP2A loss does not affect the intestinal apoptotic response following DNA damage. Shown is the scoring of a number of apoptotic cells per crypt in WT and
CIP2AHOZ intestines 6 hr post irradiation.
(H) H&E and Ki67 staining of regenerating crypts from WT and CIP2AHOZ intestines following cisplatin treatment. Scale bars, 50 mm.
(I) Scoring of a number of regenerating crypts in WT and CIP2AHOZ intestines following cisplatin treatment (Mann-Whitney, n = 6 versus 5).
(J) Scoring of a number of Ki67-positive cells per crypt in WT and CIP2AHOZ intestines following cisplatin treatment (Mann-Whitney test, n = 4).
(K) Expression ratio of CIP2A and OLFM4 mRNA in GFP-LGR5-positive/LGR5 negative intestinal crypt cells after GFP-positive cell sorting. Error bars represent
the mean ± SD.expression was quantified (Figure 6B) confirmed the significant
inhibition of expression of both of these MYC targets in regener-
ating CIP2AHOZ intestine (Figure 6I).
Together, these results provide in vivo validation that
CIP2A selectively supports the expression of serine 62-phos-
phorylated MYC.
Confirmation of the Importance of MYC Serine 62
Phosphorylation for Proliferation Induction In Vivo
To validate our main conclusion that expression of pS62MYC is
critical for proliferation induction in vivo, we again used the MYC
serine 62 phosphorylation mutants in an in vivo setting. We
hypothesized that T58A might more potently rescue the effects
of endogenous MYC loss in the intestinal regeneration model
than WT MYC and S62A MYC. We have shown recently that WT
c-myc (RosaMyc/+) transgene expression at a subphysiological1026 Cell Reports 12, 1019–1031, August 11, 2015 ª2015 The Autholevel is unable to drive a regenerative response in the absence
of endogenous, Wnt-induced c-myc (Ashton et al., 2010).
To this end, we crossed AhCre Mycfl/fl mice with mice carrying
a Lox-stop-Lox c-myc, Lox-stop-Lox c-mycT58A, and Lox-stop-
Lox c-mycS62A allele to generate Mycfl/fl RosaMyc/+, Mycfl/fl
RosaMycT58A/+, and Mycfl/fl RosaMycS62A/+ mice, respectively
(Figure S6A). This cross permits B-napthoflavone-induced
expression of either the WT, T58A, or S62A allele of MYC at sub-
physiological levels in the absence of endogenous, Wnt-induced
c-myc. Importantly, upon recombination, the transgenes were
transcriptionally expressed at the same level (Figure S6B),
whereas both T58AMYC and S62AMYC showed significantly
higher protein expression in regenerating intestine than WT
MYC (Figure 7A). Increased expression of the T58A mutant is
presumably due to its higher protein stability, whereas higher
protein expression of S62MYC than WT MYC upon tissuers
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Figure 6. CIP2A Is Critical for the Expression of Serine 62-Phosphorylated MYC and for MYC-Driven Transcriptional Activity during In Vivo
Proliferation Induction
(A) Immunohistochemical staining of MYC from untreated WT and CIP2AHOZ intestines. Scale bars, 50 mm.
(B) Immunohistochemical staining of MYC, CDK4, and TIAM1 in regenerating crypts from WT and CIP2AHOZ intestines. The dashed line outlines the crypt area
used for histoscoring. The insets show magnified images of MYC staining intensity in selected crypts. Scale bars, 50 mm.
(C) Histoscoring of the intensity of MYC immunopositivity in regenerating crypts from WT and CIP2AHOZ intestines (p = not significant, Mann-Whitney test, n = 3
versus 3).
(D) qRT-PCR analysis of MYC inWT regenerating andCIP2AHOZ regenerating small intestines (p = not significant, Student’s t test, n = 6). Error bars represent the
mean ± SD.
(E) Immunofluorescent staining for pS62MYC inWT,CIP2AHOZ, WT regenerating, andCIP2AHOZ regenerating small intestines. Ki67 was co-stained to assess the
induction of proliferation. Scale bars, 25 mm. Magnification, 320.
(F) Quantitation of pS62MYC intensity per cell from (E). Error bars represent the mean ± SD.
(G) qRT-PCR analysis for MYC target gene expression in WT regenerating and CIP2AHOZ regenerating small intestines (*p < 0.05, **p < 0.01, ***p < 0.001;
Student’s t test, n = 3). The red line represents mRNA expression levels of MYC target genes normalized to 1 in wild-type tissue. Error bars represent mean ± SD.
(H) Immunohistochemical staining of TIAM1 and CDK4 in regenerating crypts from WT, CIP2AHOZ, and Mycfl/fl intestines. Scale bars, 50 mm.
(I) Histoscoring of CDK4 and TIAM1 immunopositivity in regenerating crypts fromWT and CIP2AHOZ intestines (Mann-Whitney test, n = 6 versus 7). The data are
derived from a tissue section adjacent to that analyzed for the MYC histoscore in (B). The asterisk indicates an outlier value removed from the analysis.regeneration may be due to a compensation mechanism, as dis-
cussed below. However, despite the similar protein expression
levels of T58AMYC and S62AMYC, as assessed by a total
MYC antibody, the MYCT58A mutant did show a significantly
increased level of serine 62 phosphorylation in regenerating in-
testine tissue compared with either S62A or WT MYC (Figures
7B and 7C). This finding is consistent with data published previ-
ously (Lutterbach and Hann, 1994; Sears et al., 2000) and allows
comparison of these models to assess whether the form of MYC
that drives the highest regeneration potential in vivo is the serine
62-phosphorylatedMYC. Irradiation ofWTmice again resulted in
a robust regenerative response 72 hr later, as evidenced by large
crypts that stained positively for Ki67 (Figure 7D; Figure S6C).
However, the conditional deletion of c-myc by intraperitoneal
(i.p.) injection of B-napthoflavone (Mycfl/fl) suppressed regenera-
tion (Figure 7D; Figure S6C). As shown before (Ashton et al.,Cell2010), the B-naphtoflavone injection-elicited expression of WT
c-myc (RosaMyc/+) at a subphysiological level was unable to drive
a regenerative response (Figure 7D; Figure S6C). However,
consistent with all other data indicating that serine 62 phosphor-
ylation defines MYC’s proliferative potential, T58AMYC was
significantly more competent than the WT of S62AMYC to
compensate for the loss of endogenous c-myc, both in the
regeneration response as well as in driving cell proliferation in
response to irradiation (Figures 7D and 7E; Figure S6C). Impor-
tantly, we did not observe any gross histological differences or
proliferative effects following expression of the T58AMYC trans-
gene in untreated wild-type mice, indicating that the increased
regeneration by T58AMYC was not due to a more proliferative
environment (Figure S6D). Furthermore, in full support of our
in vitro results showing that serine 62 phosphorylation is a deter-
mining factor for whether MYC interacts with both CIP2AReports 12, 1019–1031, August 11, 2015 ª2015 The Authors 1027
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Figure 7. Analysis of MYC Knockin Mutants Support the Importance of MYC Serine 62 Phosphorylation and Lamin A/C Association for
Proliferation Induction In Vivo
(A) Quantitation of MYC immunostaining intensity in regenerating small intestine in mice with the indicated genotypes (Mann-Whitney test, n = 4 versus 4).
(B) Immunofluorescent staining for pS62MYC in regenerating small intestine in mice with the indicated genotypes. Magnification, 320.
(C) Quantitation of pS62MYC intensity from (B) (Mann-Whitney test, n = 4 versus 4).
(D) Scoring of regenerating crypts in mice with the indicated genotypes 72 hr post-irradiation.
(E) Scoring of the percentage of Ki67-positive cells per crypt in mice with the indicated genotypes 72 hr post-irradiation.
(F) PLA analysis of theMYC-Lamin A/C andMYC-CIP2A association in intestinal crypts in mice with the indicated genotypes 72 hr post-irradiation. The specificity
of PLA is shown by the lack of PLA signals in the secondary antibody-only control panel. Scale bar, 25 mm.
(G) qRT-PCR analysis for CIP2A-regulated MYC target gene expression in Mycfl/fl and Mycfl/fl RosaMycT58A/+ small intestine (*p < 0.05, **p < 0.01, ***p < 0.001;
Student’s t test; n = 3). The red line represents mRNA expression levels of CIP2A-regulated MYC target genes normalized to 1 inMycfl/fl small intestine. Error bars
represent the mean ± SD.(Junttila et al., 2007) and Lamin A/C (Figures 2A–2C), the PLA
analysis on regenerating intestinal tissues demonstrated an
almost absolute lack of LAS localization of MYCS62A, whereas
MYCT58A robustly interacted with both CIP2A and Lamin A/C
in vivo (Figure 7F). Finally, we confirmed that expression of
MYCT58A also rescued the expression of a number of CIP2A-
regulated MYC target genes that were downregulated in Mycfl/fl
intestine (Figure 7G). Importantly, among those that were
rescued was Tiam1, which was used as amodel gene to demon-
strate CIP2A’s role in MYC promoter recruitment (Figure S5).
Together, these results strongly support our main conclusions
that the form of MYC protein that drives in vivo proliferation and
DNA damage-induced regeneration is pS62MYC and that the
association of pS62MYC with both the LAS and CIP2A is inti-1028 Cell Reports 12, 1019–1031, August 11, 2015 ª2015 The Authomately linked to MYC-mediated proliferation induction and
gene expression in vivo.
DISCUSSION
The development of targeted therapies requires a thorough un-
derstanding of the molecular mechanisms regulating the target
activity as well as the validation of the importance of this mech-
anism in a faithful in vivo model. Based on extensive research
during the past three decades, it has become evident that target-
ing of MYC would be highly desirable for hyperproliferative dis-
eases (Meyer and Penn, 2008; Soucek et al., 2008). Surprisingly,
though, until now it has not been demonstrated which endoge-
nous post-translational mechanism defines MYC activity in vivo.rs
In this work, we demonstrate, by using both CIP2A and MYC
mouse models, that CIP2A-mediated support of MYC serine
62 phosphorylation is critically linked to MYC’s capacity to re-
initiate proliferation and support intestinal regeneration in
response to DNA damage. Importantly, our data indicate that
neither CIP2A nor MYC serine 62 phosphorylation impact basal
proliferation or differentiation of intestinal crypt cells. Therefore,
MYC serine 62 phosphorylation appears to be selectively
required to support MYC-mediated high-level proliferation. In
addition to their biological importance, these results indicate
that selective targeting of mechanisms that support serine 62
phosphorylation MYCmight constitute a therapy strategy for hy-
perproliferative diseases. Specifically, the results indicate that
targeting CIP2A could offer a possibility to interfere with MYC-
mediated proliferation without detrimental consequences on
normal physiology. However, we cannot currently exclude that,
in addition to MYC, inhibition of other CIP2A-regulated proteins
(Khanna et al., 2013; Puustinen et al., 2014) could also partly
contribute to the in vivo effects of CIP2A inhibition in intestinal
regeneration. On the other hand, the results imply that pharma-
ceutical inhibition of CIP2A might affect the regeneration of
normal tissues when combined with DNA-damaging anticancer
drugs. Therefore, targeting of CIP2A should be combined, for
example, with localized radiotherapy specifically targeting the
tumor tissue. In support of the importance of CIP2A in mediating
radioresistance in human cancers, we recently published a study
showing that high expression of tumor CIP2A and stem cell fac-
tor Oct4 predicts poor patient survival in cancer patients treated
with radiotherapy (Ventela et al., 2015).
Even though serine 62 phosphorylation regulates MYC stabil-
ity in cultured cells (Hann, 2006; Sears et al., 2000), our data
show that, upon irradiation-induced proliferation in vivo, loss
of endogenous MYC serine 62 phosphorylation by CIP2A inhibi-
tion does not abrogate total MYC expression (Figures 6B and
6C). Interestingly, the S62AMYC mutant also did not show
a significant difference in protein expression compared with
T58AMYC. We speculate that either there is a fundamental dif-
ference in the role of serine 62 phosphorylation or MYC in its sta-
bility regulation between the in vitro and in vivo context or that,
upon loss of serine 62 phosphorylation in vivo, intestinal cells un-
der DNA damage-induced stress compensate for the situation
by increasing the expression of MYC that is not phosphorylated
on serine 62 by a still unknown mechanism. We also cannot
exclude that the non-significant decreased median expression
of S62AMYC may, in part, contribute to the proliferation defect
caused by loss of serine 62 phosphorylation. We even noted
some focus-positive staining with pS62MYC antibody in the nu-
cleus of MYCfl/fl mice, and this can be due to compensatory
expression of NMYC because the sequences surrounding serine
62 are nearly 100% conserved between MYC and NMYC.
Importantly, the cell culture experiments revealed a plausible
explanation for the selectivity of CIP2A toward pS62MYC. We
show that serine 62 phosphorylation promotes MYC recruitment
to the LAS and that only pS62MYC associated with the LAS is
sensitive to regulation by CIP2A, whereas MYC in the soluble
nuclear fraction was resistant to CIP2A depletion. Importantly,
the preferential association of T58AMYC, exhibiting increased
serine 62 phosphorylation, with the LAS and CIP2A was vali-Celldated in vivo (Figure 7F). Most importantly, the functional out-
comes of both the CIP2AHOZ and S62AMYC models perfectly
support the overall conclusions of this work that, when MYC is
phosphorylated on serine 62, it interacts with both LAS and
CIP2A and that this biochemical form of MYC drives in vivo pro-
liferation and regeneration.
Consistent with an emerging picture of nuclear lamin-associ-
ated domains as critical structures for gene regulation and chro-
matin remodeling (Kind et al., 2013; Shimi et al., 2010; Zullo et al.,
2012), our data indicate that CIP2A-MYC interaction at the LAS is
essential for maintaining transcription-competent MYC that sub-
sequently binds to its target promoters to promote the expres-
sion of proliferation-inducing genes. Importantly, recent studies
have also indicated that serine 62 phosphorylation of MYC may
affect target promoter selection (Benassi et al., 2006; Farrell
et al., 2013), which is another interesting aspect to study in the
future by using a CIP2A-deficient mouse model. Also, the asso-
ciation of CIP2A with nuclear pores (data not shown; Thakar
et al., 2013) is consistent with the recent indication that multipro-
tein platforms at nuclear pores are key regulators of the DNA
damage response (Arib and Akhtar, 2011; Bukata et al., 2013).
Of historical note, association of MYC with the nuclear envelope
has been demonstrated previously (Eisenman et al., 1985;
Winqvist et al., 1984), and MYC stability has been linked to its
subnuclear partitioning (Tworkowski et al., 2002), but the physi-
ological relevance of these findings has so far been obscure.
In summary, these results demonstrate that MYC serine 62
phosphorylation is a non-essential mechanism that supports
MYC’s proliferative activity in vivo. Because CIP2A supports
pS62MYC expression and other oncogenic driver phosphoryla-
tion events (Khanna et al., 2013) but is non-essential in normal
physiology, the development of chemical inhibitors of CIP2A is
a prospective approach for the inhibition of proliferation in vivo
without therapy-limiting side effects. We also envision that our
results will provoke future studies to identify other therapeutic
strategies to inhibit MYC serine 62 phosphorylation. Moreover,
our demonstration that transcription factor function and accu-
mulation are regulated at the LAS suggests the potential for
targeting these structures for future therapies. Finally, our data
demonstrate CIP2A as a signaling protein that is indispensable
for the efficient recovery and regeneration of intestinal tissue
in response to DNA damage, implying an important role for
CIP2A in organismal DNA damage response.
EXPERIMENTAL PROCEDURES
Mouse Experiments
All experiments were performed under UK Home Office guidelines. All mice
used were of a mixed background (50% C57BlJ, 50% S129). The alleles
used for this study were as follows: c-Mycfl (de Alboran et al., 2001), AhCre
(Ireland et al., 2004), RosaMyc (Wang et al., 2011), RosaMycT58 (Wang et al.,
2011), and CIP2AHOZ (Ventela¨ et al., 2012). To determine the role of Myc pro-
tein stability during intestinal regeneration, AhCre c-Mycfl/fl mice were crossed
to RosaMyc, RosaMycT58A, or RosaMycS62A mice. Control, AhCre c-Mycfl/fl,
AhCre c-Mycfl/fl RosaMyc/+, AhCre c-Mycfl/fl RosaMycT58A/+, or AhCre c-Mycfl/fl
RosaMycS62A/+ mice were given three i.p. injections of 80 mg/kg b-napthofla-
vone in a single day, which yields nearly constitutive recombination in the
murine small intestine. Intestinal regeneration experiments have been
described previously (Myant et al., 2013), and the protocol is included in the
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Immunohistochemistry
Standard immunohistochemistry techniques were used throughout this study.
The primary antibodies used for immunohistochemistry were as follows: Ki67
(Vector Laboratories, catalog no. VP-K452), c-Myc (Santa Cruz Biotechnology,
catalog no. sc-764), BrdUrd (BD Biosciences), CDK4 (Santa Cruz, catalog no.
sc-260), Tiam1 (Santa Cruz, sc-872), CIP2A (Junttila et al., 2007; Laine et al.,
2013; Soo Hoo et al., 2002; Ventela¨ et al., 2012), and pS62MYC(Junttila
et al., 2007; Wang et al., 2011; Yeh et al., 2004). Immunohistochemistry was
performed on formalin-fixed intestinal sections. For each antibody, staining
was performed on at least three mice of each genotype. For histoscoring,
the average staining intensity in 50 consecutive crypts was scored from at
least six mice. For MYC serine 62 phosphorylation, the fluorescent signals
for pS62MYC intensity and 40,6-diamidino-2-phenylindole (DAPI) intensity
were calculated from four slides, each representing a different treatment/
phenotype. From these, ten pictures per slide were taken, and from each pic-
ture, nucleus staining was quantified by drawing a circle around 20 nuclei using
the OpenLab 5.5 software, and the signal intensity was measured from 50
nuclei/crypt from each picture using ImageJ. MYC phosphorylation status is
expressed as the pS62MYC/DAPI ratio using the average intensity from all
measurements per treatment/genotype. Error bars represent the averaged
intensity calculated in four mice. Similar results were obtained from two inde-
pendent series of experiments performed one year apart. Representative im-
ages are shown for each staining. The scale bars in all figures represent 50 mm.
Proximity Ligation Assay and Immunofluorescence Staining
The PLA assay was performed according to themanufacturer’s protocol (Olink
Bioscience). Briefly, cells plated on coverslips were grown to 70% confluence,
fixed with 3:1 acetone methanol at 20C for 5–7 min, blocked with blocking
solution, and incubated in a pre-heated humidity chamber for 30 min at 37C,
followed by incubating the primary antibodies (in blocking solution) anti-CIP2A
(Soo Hoo et al., 2002), anti-CIP2A (catalog no. sc-80659, Santa Cruz), anti-
MYC (catalog no. 9E10, Sigma), anti-Lamin A/C (goat, catalog no. sc-6215,
Santa Cruz), anti-LAP2 (catalog no. 611000, BD Transduction Laboratories),
anti-Lamin A/C (636, mouse, catalog no. sc-7292, Santa Cruz), anti-Lamin
A/C (H-110, rabbit, catalog no. sc-20681, Santa Cruz), and anti-c-Myc (phos-
phoserine 62, mouse, catalog no. ab78318, Abcam) overnight at 4C. Subse-
quently, cells were washed with buffer A, and the PLA probe was incubated in
a pre-heated humidity chamber for 1 hr at 37C, followed by ligase reaction in a
pre-heated humidity chamber for 1 hr at 37C. Next, amplification polymerase
solution for PLA and the secondary antibody Alexa Fluor 488 (Invitrogen) for
Lamin A/C (goat, catalog no. sc-6215, Santa Cruz), used for CIP2A-MYC
and CIP2A-pS62MYC PLA, were added, followed by incubating the cells in
a pre-heated humidity chamber for 100 min at 37C.
For tissue samples, formalin-fixed slides were dewaxed in xylene and rehy-
drated in decreasing concentrations of alcohol, followed by washing two times
in tap water. The slides were then incubated in antigen retrieval buffer (Lab
Vision citrate buffer, Thermo Scientific) for 30 min at 99C, followed by cooling
down to room temperature and rinsing the slides in distilled water (dH2O).
Next, the slides were blocked for 15 min in 1.5% H2O2 solution in PBS,
followed by rising in dH2O and rinsing once in Tris-buffered saline with Tween
20 (TBST) buffer. Finally, the PLA assay was performed following the PLA pro-
tocol for cell staining from blocking slides by blocking solution. Immunofluo-
rescence for CIP2A, MYC (catalog no. sc-764, Santa Cruz), pS62MYC (catalog
no. ab51156, Abcam), and Lamin A/C (catalog no. sc-7292, Santa Cruz) was
performed as described previously (Junttila et al., 2007). All fluorescent stain-
ings were analyzed using a confocal microscope (LSM780, Carl Zeiss).
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